AdVac-based vaccine is now in a Phase I trial.
Crucell will receive up to $5 million from Aeras Global TB Vaccine Foundation to support the advanced development of the candidate AdVac-based tuberculosis vaccine.
“This technology, which is based on one of the most advanced vector delivery systems for induction of cellular immunity, represents an important part of the portfolio of vaccines we are developing against tuberculosis,” states Jerald C. Sadoff, president & CEO of Aeras Global TB Vaccine Foundation.
In March 2004, Aeras and Crucell entered into a collaborative agreement for the development of a PER.C6® and AdVac®-based TB vaccine. The vaccine entered a Phase I trial in October 2006.
